160 results on '"Wicks IP"'
Search Results
2. Characterization of a human synovial cell antigen: VCAM‐1 and inflammatory arthritis
- Author
-
Carter, RA, primary, O'Donnell, K, additional, Sachthep, S, additional, Cicuttini, F, additional, Boyd, AW, additional, and Wicks, IP, additional
- Published
- 2001
- Full Text
- View/download PDF
3. Autoimmune regulator controls T cell help for pathogenetic autoantibody production in collagen-induced arthritis.
- Author
-
Campbell IK, Kinkel SA, Drake SF, Nieuwenhuijze AV, Hubert FX, Tarlinton DM, Heath WR, Scott HS, and Wicks IP
- Abstract
OBJECTIVE: Autoimmune regulator (Aire) promotes the ectopic expression of tissue-restricted antigens in medullary thymic epithelial cells (mTECs), leading to negative selection of autoreactive T cells. This study was undertaken to determine whether loss of central tolerance renders Aire-deficient (Aire(-/-)) mice more susceptible to the induction of autoimmune arthritis. METHODS: Medullary TECs were isolated from Aire(-/-) and wild-type C57BL/6 mice for gene expression analysis. Collagen-induced arthritis (CIA) was elicited by injection of chick type II collagen (CII) in adjuvant. Cellular and humoral immune responses to CII were evaluated. Chimeric mice were created by reconstituting lymphocyte-deficient mice with either Aire(-/-) or wild-type CD4 T cells and wild-type B cells. RESULTS: Wild-type, but not Aire(-/-), mTECs expressed the CII gene Col2a1. Aire(-/-) mice developed more rapid and severe CIA, showing elevated serum anti-CII IgG levels, with earlier switching to arthritogenic IgG subclasses. No evidence was found of enhanced T cell responsiveness to CII in Aire(-/-) mice; however, Aire(-/-) CD4 T cells were more efficient at stimulating wild-type B cells to produce anti-CII IgG following immunization of chimeric mice with CII. CONCLUSION: Our findings indicate that Aire-dependent expression of CII occurs in mTECs, implying that there is central tolerance to self antigens found in articular cartilage. Reduced central tolerance to CII in Aire(-/-) mice manifests as increased CD4 T cell help to B cells for cross-reactive autoantibody production and enhanced CIA. Aire and central tolerance help prevent cross-reactive autoimmune responses to CII initiated by environmental stimuli and limit spontaneous autoimmunity. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
4. Prevalence and cost of musculoskeletal disorders: a population-based, public hospital system healthcare consumption approach.
- Author
-
Osborne RH, Nikpour M, Busija L, Sundararajan V, and Wicks IP
- Published
- 2007
5. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis.
- Author
-
Wong PKK, Quinn JMW, Sims NA, Nieuwenhuijze A, Campbell IK, and Wicks IP
- Abstract
OBJECTIVE: To determine the cellular mediators of antigen-induced arthritis (AIA) and the relative contribution of members of the interleukin-6 (IL-6) family and tumor necrosis factor (TNF) in AIA. METHODS: AIA was induced in mice deficient in T and B lymphocytes, IL-6 (IL-6(-/-)), TNF (TNF(-/-)), IL-11 receptor, and oncostatin M receptor, by immunization with methylated bovine serum albumin (mBSA) followed 7 days later by intraarticular injection of mBSA. Arthritis severity was assessed histologically, and T lymphocyte responses were assessed in vitro. Anti-TNF neutralizing antibody was administered to wild-type mice during AIA. Bone marrow osteoclasts were generated in vitro via culture with RANKL and macrophage colony-stimulating factor. RESULTS: AIA was dependent on CD4+ T lymphocytes, but not CD8+ T lymphocytes or B cells. IL-6(-/-) mice had reduced AIA severity and fewer osteoclasts at sites of bone erosion. This protective effect was not seen with a deficiency of other IL-6 family members and was similar to that in TNF(-/-) mice or wild-type mice receiving TNF blockade treatment. IL-6(-/-) CD4+ T lymphocytes from draining lymph nodes had reduced antigen-induced proliferation and produced less IL-17 and less RANKL, relative to osteoprotegerin, than cells from wild-type mice. Bone marrow from IL-6(-/-) mice generated fewer osteoclasts in vitro than bone marrow from either wild-type or TNF(-/-) mice. CONCLUSION: AIA is driven by CD4+ T lymphocytes. IL-6 is an important mediator of bone destruction in AIA because it regulates T lymphocyte production of key osteoclastogenic cytokines and inflammation-induced bone marrow osteoclast differentiation. These findings have implications for reducing bone and joint damage in rheumatoid arthritis. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
6. Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitors factor.
- Author
-
Lawlor KE, Wong PKK, Campbell IK, van Rooijen N, and Wicks IP
- Abstract
OBJECTIVE: To further investigate the effects of interleukin-1 (IL-1) in immune-mediated joint inflammation, we examined the role of IL-2, Th1 interferon-gamma (IFNgamma), and Th2 (IL-4) cytokines, joint macrophages, and macrophage-derived cytokines (IL-12 p40, IL-6, leukemia inhibitory factor [LIF], oncostatin M [OSM], and granulocyte-macrophage colony-stimulating factor [GM-CSF]) in a CD4+ T lymphocyte-dependent model of acute arthritis. METHODS: Methylated bovine serum albumin (mBSA)/IL-1-induced arthritis was elicited in wild-type, gene-knockout, and monoclonal antibody-treated mice. Synovial lining macrophages were selectively depleted by intraarticular injection of clodronate liposomes prior to disease induction. The severity of arthritis was assessed histologically. RESULTS: Mice deficient in IL-2 were almost completely protected from arthritis, and neutralization of IL-4 reduced the severity of disease. In contrast, arthritis severity and resolution appeared to be independent of IFNgamma. Synovial lining macrophage depletion markedly reduced arthritis severity. IL-6 or LIF deficiency was only modestly protective, although as previously reported, GM-CSF deficiency conferred profound disease resistance. IL-12 p40-deficient mice (which lack IL-12 and IL-23) and OSM receptor-deficient mice were susceptible to mBSA/IL-1-induced arthritis. CONCLUSION: Acute mBSA/IL-1-induced arthritis is dependent on IL-2 and IL-4, but not IFNgamma. In vivo, the Th1/Th2 paradigm may be distorted by the presence of macrophage-derived cytokines such as IL-1. Synovial lining macrophages are essential in mBSA/IL-1-induced arthritis. However, the requirement for macrophage-derived cytokines is selective; that is, IL-6, LIF, and especially GM-CSF are necessary, but IL-12, IL-23, and OSM are dispensable. IL-1 may therefore influence both adaptive and innate immune mechanisms in acute inflammatory arthritis. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
7. Severely compromised quality of life in women and those of lower socioeconomic status waiting for joint replacement surgery.
- Author
-
Ackerman IN, Graves SE, Wicks IP, Bennell KL, and Osborne RH
- Published
- 2005
8. Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIa-transgenic mice.
- Author
-
Sardjono CT, Mottram PL, van de Velde NC, Powell MS, Power D, Slocombe RF, Wicks IP, Campbell IK, McKenzie SE, Brooks M, Steenson AW, and Hogarth PM
- Abstract
OBJECTIVE: The major human Fc receptor, FcgammaRIIa, is the most widespread activating FcR. Our aim was to determine the role of FcgammaRIIa in a transgenic mouse model of immune complex-mediated autoimmunity and to characterize the development of spontaneous autoimmune disease. METHODS: Arthritis was induced in normal and FcgammaRIIa-transgenic mice by immunization with type II collagen (CII) or by transfer of arthritogenic anti-CII antibodies. Also, mice that spontaneously developed autoimmune disease were assessed by clinical scoring of affected limbs, histology and serology, and measurement of autoantibody titers and cytokine production. RESULTS: FcgammaRIIa-transgenic mice developed collagen-induced arthritis (CIA) more rapidly than did archetypal CIA-sensitive DBA/1 (H-2q) mice, while nontransgenic C57BL/6 (H-2b) mice did not develop CIA when similarly immunized. Passive transfer of a single dose of anti-CII antibody induced a more rapid, severe arthritis in FcgammaRIIa-transgenic mice than in nontransgenic animals. In addition, most immune complex-induced production of tumor necrosis factor alpha by activated macrophages occurred via FcgammaRIIa, not the endogenous mouse FcR. A spontaneous, multisystem autoimmune disease developed in aging (>20 weeks) transgenic mice (n = 25), with a 32% incidence of arthritis, and by 45 weeks, all mice had developed glomerulonephritis and pneumonitis, and most had antihistone antibodies. Elevated IgG2a levels were seen in mice with CIA and in those with spontaneous disease. CONCLUSION: The presence of enhanced passive and induced autoimmunity, as well as the emergence of spontaneous autoimmune disease at 20-45 weeks of age, suggest that FcgammaRIIa is a very important factor in the pathogenesis of autoimmune inflammation and a possible target for therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
9. Characterization of a human synovial cell antigen: VCAM-1 and inflammatory arthritis.
- Author
-
Wicks, I, Carter, RA, O'Donnell, K, Sachthep, S, Cicuttini, F, Boyd, AW, and Wicks, IP
- Subjects
RHEUMATOID arthritis ,CELLS ,MONOCLONAL antibody probes ,CELL adhesion molecules - Abstract
SummaryThe contribution of synovial cells to the pathogenesis of rheumatoid arthritis (RA) is only partly understood. Monoclonal antibody (mAb) 1D5 is one of very few mAb ever raised against RA synovial cells in order to study the biology of these cells. Studies on the expression pattern and structural features of the 1D5 Ag suggest that 1D5 recognizes human vascular cell adhesion molecule-1 (VCAM-1), which is an intercellular adhesion molecule. Vascular cell adhesion molecule-1 may be involved in a number of crucial intercellular interactions in RA. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
10. Sustained remission, possibly cure, of seronegative arthritis after high-dose chemotherapy and syngeneic hematopoietic stem cell transplantation.
- Author
-
McColl GJ, Szer J, and Wicks IP
- Published
- 2005
- Full Text
- View/download PDF
11. mTOR signalling controls the formation of smooth muscle cell-derived luminal myofibroblasts during vasculitis.
- Author
-
Stock AT, Parsons S, Hansen JA, D'Silva DB, Starkey G, Fayed A, Lim XY, D'Costa R, Gordon CL, and Wicks IP
- Abstract
The accumulation of myofibroblasts within the intimal layer of inflamed blood vessels is a potentially catastrophic complication of vasculitis, which can lead to arterial stenosis and ischaemia. In this study, we have investigated how these luminal myofibroblasts develop during Kawasaki disease (KD), a paediatric vasculitis typically involving the coronary arteries. By performing lineage tracing studies in a murine model of KD, we reveal that luminal myofibroblasts develop independently of adventitial fibroblasts and endothelial cells, and instead derive from smooth muscle cells (SMCs). Notably, the emergence of SMC-derived luminal myofibroblasts-in both mice and patients with KD, Takayasu's arteritis and Giant Cell arteritis-coincided with activation of the mechanistic target of rapamycin (mTOR) signalling pathway. Moreover, SMC-specific deletion of mTOR signalling, or pharmacological inhibition, abrogated the emergence of luminal myofibroblasts. Thus, mTOR is an intrinsic and essential regulator of luminal myofibroblast formation that is activated in vasculitis patients and therapeutically tractable. These findings provide molecular insight into the pathogenesis of coronary artery stenosis and identify mTOR as a therapeutic target in vasculitis., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
12. An immunohistochemical atlas of necroptotic pathway expression.
- Author
-
Chiou S, Al-Ani AH, Pan Y, Patel KM, Kong IY, Whitehead LW, Light A, Young SN, Barrios M, Sargeant C, Rajasekhar P, Zhu L, Hempel A, Lin A, Rickard JA, Hall C, Gangatirkar P, Yip RK, Cawthorne W, Jacobsen AV, Horne CR, Martin KR, Ioannidis LJ, Hansen DS, Day J, Wicks IP, Law C, Ritchie ME, Bowden R, Hildebrand JM, O'Reilly LA, Silke J, Giulino-Roth L, Tsui E, Rogers KL, Hawkins ED, Christensen B, Murphy JM, and Samson AL
- Subjects
- Animals, Humans, Mice, Protein Kinases metabolism, Protein Kinases genetics, Caspase 8 metabolism, Signal Transduction, Mice, Inbred C57BL, Necroptosis, Receptor-Interacting Protein Serine-Threonine Kinases metabolism, Receptor-Interacting Protein Serine-Threonine Kinases genetics, Immunohistochemistry methods
- Abstract
Necroptosis is a lytic form of regulated cell death reported to contribute to inflammatory diseases of the gut, skin and lung, as well as ischemic-reperfusion injuries of the kidney, heart and brain. However, precise identification of the cells and tissues that undergo necroptotic cell death in vivo has proven challenging in the absence of robust protocols for immunohistochemical detection. Here, we provide automated immunohistochemistry protocols to detect core necroptosis regulators - Caspase-8, RIPK1, RIPK3 and MLKL - in formalin-fixed mouse and human tissues. We observed surprising heterogeneity in protein expression within tissues, whereby short-lived immune barrier cells were replete with necroptotic effectors, whereas long-lived cells lacked RIPK3 or MLKL expression. Local changes in the expression of necroptotic effectors occurred in response to insults such as inflammation, dysbiosis or immune challenge, consistent with necroptosis being dysregulated in disease contexts. These methods will facilitate the precise localisation and evaluation of necroptotic signaling in vivo., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. Muscle biopsy practices in the evaluation of idiopathic inflammatory myopathies: An international survey of expert clinicians.
- Author
-
Maxwell S, Ross L, Oon S, Wicks IP, and Day J
- Subjects
- Humans, Biopsy, Surveys and Questionnaires, Practice Patterns, Physicians' statistics & numerical data, Myositis diagnosis, Myositis pathology, Muscle, Skeletal pathology
- Abstract
Background: Muscle biopsy is an important test in the evaluation of individuals with suspected myopathy, including those with suspected idiopathic inflammatory myopathy (IIM). Various approaches, including open surgical biopsy, needle biopsy and conchotome forceps, have been reported. However the real-world utilisation of these approaches remains unclear. There are no established guidelines for the use of muscle biopsy, or selection of biopsy technique, in investigating IIM and international practices are not well-documented. This study describes current approaches to muscle biopsy amongst clinicians with expertise in IIM., Methods: A survey regarding muscle biopsy practices was disseminated among members of the International Myositis Assessment and Clinical Studies (IMACS) group. Data were analysed using descriptive statistics., Results: One-hundred and sixteen clinicians completed the survey, primarily rheumatologists. Open surgical biopsy was the most commonly employed technique (74.5 %), followed by needle (11.3 %) and conchotome (9.4 %) approaches. Clinical examination was the most common method of muscle selection, with 85.2 % of respondents reporting they 'always or almost always' relied on it. MRI and electromyography were also frequently utilised for muscle selection (51.9 %, 45.4 % respectively). There was variability in the perceived utility of muscle biopsy in certain clinical contexts, such as presence of myositis specific antibodies or cutaneous manifestations of dermatomyositis. While respondents generally reported low complication rates following muscle biopsy, non-diagnostic histopathology was commonly reported, regardless of procedural approach., Conclusion: Clinicians managing IIM report muscle biopsy to be well tolerated however, non-diagnostic results are common. Substantial heterogeneity regarding perceived indications for biopsy, procedural approaches, and muscle selection strategies were observed within this expert group. Future research is needed to establish best practice and determine the role of muscle biopsy in the context of continued advancements in serological profiling of IIM., Competing Interests: Declaration of competing interest The authors have no competing interests to declare., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
14. A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation.
- Author
-
Garnish SE, Martin KR, Kauppi M, Jackson VE, Ambrose R, Eng VV, Chiou S, Meng Y, Frank D, Tovey Crutchfield EC, Patel KM, Jacobsen AV, Atkin-Smith GK, Di Rago L, Doerflinger M, Horne CR, Hall C, Young SN, Cook M, Athanasopoulos V, Vinuesa CG, Lawlor KE, Wicks IP, Ebert G, Ng AP, Slade CA, Pearson JS, Samson AL, Silke J, Murphy JM, and Hildebrand JM
- Subjects
- Humans, Animals, Mice, Phosphorylation, Cell Membrane metabolism, Mutation, Transcription Factors metabolism, Receptor-Interacting Protein Serine-Threonine Kinases metabolism, Protein Kinases genetics, Protein Kinases metabolism, Apoptosis
- Abstract
Across the globe, 2-3% of humans carry the p.Ser132Pro single nucleotide polymorphism in MLKL, the terminal effector protein of the inflammatory form of programmed cell death, necroptosis. Here we show that this substitution confers a gain in necroptotic function in human cells, with more rapid accumulation of activated MLKL
S132P in biological membranes and MLKLS132P overriding pharmacological and endogenous inhibition of MLKL. In mouse cells, the equivalent Mlkl S131P mutation confers a gene dosage dependent reduction in sensitivity to TNF-induced necroptosis in both hematopoietic and non-hematopoietic cells, but enhanced sensitivity to IFN-β induced death in non-hematopoietic cells. In vivo, MlklS131P homozygosity reduces the capacity to clear Salmonella from major organs and retards recovery of hematopoietic stem cells. Thus, by dysregulating necroptosis, the S131P substitution impairs the return to homeostasis after systemic challenge. Present day carriers of the MLKL S132P polymorphism may be the key to understanding how MLKL and necroptosis modulate the progression of complex polygenic human disease., (© 2023. Springer Nature Limited.)- Published
- 2023
- Full Text
- View/download PDF
15. G-CSF drives autoinflammation in APLAID.
- Author
-
Mulazzani E, Kong K, Aróstegui JI, Ng AP, Ranathunga N, Abeysekera W, Garnham AL, Ng SL, Baker PJ, Jackson JT, Lich JD, Hibbs ML, Wicks IP, Louis C, and Masters SL
- Subjects
- Animals, Mice, Cytokines, Interleukin-1, Tumor Necrosis Factor-alpha genetics, Immunologic Deficiency Syndromes genetics, Immunologic Deficiency Syndromes immunology, Immunologic Deficiency Syndromes metabolism, Bone Marrow Transplantation, Granulocyte Colony-Stimulating Factor
- Abstract
Missense mutations in PLCG2 can cause autoinflammation with phospholipase C gamma 2-associated antibody deficiency and immune dysregulation (APLAID). Here, we generated a mouse model carrying an APLAID mutation (p.Ser707Tyr) and found that inflammatory infiltrates in the skin and lungs were only partially ameliorated by removing inflammasome function via the deletion of caspase-1. Also, deleting interleukin-6 or tumor necrosis factor did not fully prevent APLAID mutant mice from autoinflammation. Overall, these findings are in accordance with the poor response individuals with APLAID have to treatments that block interleukin-1, JAK1/2 or tumor necrosis factor. Cytokine analysis revealed increased granulocyte colony-stimulating factor (G-CSF) levels as the most distinct feature in mice and individuals with APLAID. Remarkably, treatment with a G-CSF antibody completely reversed established disease in APLAID mice. Furthermore, excessive myelopoiesis was normalized and lymphocyte numbers rebounded. APLAID mice were also fully rescued by bone marrow transplantation from healthy donors, associated with reduced G-CSF production, predominantly from non-hematopoietic cells. In summary, we identify APLAID as a G-CSF-driven autoinflammatory disease, for which targeted therapy is feasible., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
16. Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis.
- Author
-
Dragoljevic D, Lee MKS, Pernes G, Morgan PK, Louis C, Shihata W, Huynh K, Kochetkova AA, Bell PW, Mellett NA, Meikle PJ, Lancaster GI, Kraakman MJ, Nagareddy PR, Hanaoka BY, Wicks IP, and Murphy AJ
- Abstract
Objectives: The leading cause of mortality in patients with rheumatoid arthritis is atherosclerotic cardiovascular disease (CVD). We have shown that murine arthritis impairs atherosclerotic lesion regression, because of cellular cholesterol efflux defects in haematopoietic stem and progenitor cells (HSPCs), causing monocytosis and impaired atherosclerotic regression. Therefore, we hypothesised that improving cholesterol efflux using a Liver X Receptor (LXR) agonist would improve cholesterol efflux and improve atherosclerotic lesion regression in arthritis., Methods: Ldlr
-/- mice were fed a western-type diet for 14 weeks to initiate atherogenesis, then switched to a chow diet to induce lesion regression and divided into three groups; (1) control, (2) K/BxN serum transfer inflammatory arthritis (K/BxN) or (3) K/BxN arthritis and LXR agonist T0901317 daily for 2 weeks., Results: LXR activation during murine inflammatory arthritis completely restored atherosclerotic lesion regression in arthritic mice, evidenced by reduced lesion size, macrophage abundance and lipid content. Mechanistically, serum from arthritic mice promoted foam cell formation, demonstrated by increased cellular lipid accumulation in macrophages and paralleled by a reduction in mRNA of the cholesterol efflux transporters Abca1 , Abcg1 and Apoe . T0901317 reduced lipid loading and increased Abca1 and Abcg1 expression in macrophages exposed to arthritic serum and increased ABCA1 levels in atherosclerotic lesions of arthritic mice. Moreover, arthritic clinical score was also attenuated with T0901317., Conclusion: Taken together, we show that the LXR agonist T0901317 rescues impaired atherosclerotic lesion regression in murine arthritis because of enhanced cholesterol efflux transporter expression and reduced foam cell development in atherosclerotic lesions., Competing Interests: The authors declare no conflicts of interest., (© 2023 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)- Published
- 2023
- Full Text
- View/download PDF
17. MLKL deficiency protects against low-grade, sterile inflammation in aged mice.
- Author
-
Tovey Crutchfield EC, Garnish SE, Day J, Anderton H, Chiou S, Hempel A, Hall C, Patel KM, Gangatirkar P, Martin KR, Li Wai Suen CSN, Garnham AL, Kueh AJ, Wicks IP, Silke J, Nachbur U, Samson AL, Murphy JM, and Hildebrand JM
- Subjects
- Mice, Humans, Female, Animals, Infant, Necrosis metabolism, Mice, Inbred C57BL, Cell Death, Transcription Factors metabolism, Receptor-Interacting Protein Serine-Threonine Kinases metabolism, Protein Kinases metabolism, Inflammation pathology
- Abstract
MLKL and RIPK3 are the core signaling proteins of the inflammatory cell death pathway, necroptosis, which is a known mediator and modifier of human disease. Necroptosis has been implicated in the progression of disease in almost every physiological system and recent reports suggest a role for necroptosis in aging. Here, we present the first comprehensive analysis of age-related histopathological and immunological phenotypes in a cohort of Mlkl
-/- and Ripk3-/- mice on a congenic C57BL/6 J genetic background. We show that genetic deletion of Mlkl in female mice interrupts immune system aging, specifically delaying the age-related reduction of circulating lymphocytes. -Seventeen-month-old Mlkl-/- female mice were also protected against age-related chronic sterile inflammation in connective tissue and skeletal muscle relative to wild-type littermate controls, exhibiting a reduced number of immune cell infiltrates in these sites and fewer regenerating myocytes. These observations implicate MLKL in age-related sterile inflammation, suggesting a possible application for long-term anti-necroptotic therapy in humans., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
18. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
- Author
-
Fairley JL, Nikpour M, Mack HG, Brosnan M, Saracino AM, Pellegrini M, and Wicks IP
- Subjects
- Humans, Hydroxychloroquine adverse effects, Friends, COVID-19 Drug Treatment, Chloroquine adverse effects, Antirheumatic Agents adverse effects, COVID-19, Lupus Erythematosus, Systemic drug therapy
- Abstract
Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long-term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID-19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice., (© 2022 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.)
- Published
- 2023
- Full Text
- View/download PDF
19. Mechanistic Target of Rapamycin Inhibition Prevents Coronary Artery Remodeling in a Murine Model of Kawasaki Disease.
- Author
-
Stock AT, Parsons S, D'Silva DB, Hansen JA, Sharma VJ, James F, Starkey G, D'Costa R, Gordon CL, and Wicks IP
- Subjects
- Humans, Animals, Mice, Coronary Vessels pathology, Sirolimus pharmacology, Disease Models, Animal, TOR Serine-Threonine Kinases, Mucocutaneous Lymph Node Syndrome drug therapy, Coronary Artery Disease
- Abstract
Objective: Remodeling of the coronary arteries is a common feature in severe cases of Kawasaki disease (KD). This pathology is driven by the dysregulated proliferation of vascular fibroblasts, which can lead to coronary artery aneurysms, stenosis, and myocardial ischemia. We undertook this study to investigate whether inhibiting fibroblast proliferation might be an effective therapeutic strategy to prevent coronary artery remodeling in KD., Method: We used a murine model of KD (induced by the injection of the Candida albicans water-soluble complex [CAWS]) and analyzed patient samples to evaluate potential antifibrotic therapies for KD., Results: We identified the mechanistic target of rapamycin (mTOR) pathway as a potential therapeutic target in KD. The mTOR inhibitor rapamycin potently inhibited cardiac fibroblast proliferation in vitro, and vascular fibroblasts up-regulated mTOR kinase signaling in vivo in the CAWS mouse model of KD. We evaluated the in vivo efficacy of mTOR inhibition and found that the therapeutic administration of rapamycin reduced vascular fibrosis and intimal hyperplasia of the coronary arteries in CAWS-injected mice. Furthermore, the analysis of cardiac tissue from KD fatalities revealed that vascular fibroblasts localizing with inflamed coronary arteries up-regulate mTOR signaling, confirming that the mTOR pathway is active in human KD., Conclusion: Our findings demonstrate that mTOR signaling contributes to coronary artery remodeling in KD, and that targeting this pathway offers a potential therapeutic strategy to prevent or restrict this pathology in high-risk KD patients., (© 2022 American College of Rheumatology.)
- Published
- 2023
- Full Text
- View/download PDF
20. CD98 defines a metabolically flexible, proinflammatory subset of low-density neutrophils in systemic lupus erythematosus.
- Author
-
Martin KR, Day JA, Hansen JA, D'Silva DB, Wong HL, Garnham A, Sandow JJ, Nijagal B, Wilson N, and Wicks IP
- Subjects
- Humans, Cytokines metabolism, Granulocyte Colony-Stimulating Factor metabolism, Proteomics, Lupus Erythematosus, Systemic, Neutrophils metabolism, Fusion Regulatory Protein-1 metabolism
- Abstract
Background: Low-density neutrophils (LDN) are a distinct subset of neutrophils rarely detected in healthy people but appear in the blood of patients with autoimmune diseases, including systemic lupus erythematosus (SLE), and are mobilised in response to granulocyte colony-stimulating factor (G-CSF). The aim of this study was to identify novel mechanisms responsible for the pathogenic capacity of LDN in SLE., Methods: Neutrophils were isolated from donors treated with G-CSF, and whole-cell proteomic analysis was performed on LDN and normal-density neutrophils., Results: CD98 is significantly upregulated in LDN from G-CSF donors and defines a subset of LDN within the blood of SLE patients. CD98 is a transmembrane protein that dimerises with L-type amino acid transporters. We show that CD98 is responsible for the increased bioenergetic capacity of LDN. CD98 on LDN mediates the uptake of essential amino acids that are used by mitochondria to produce adenosine triphosphate, especially in the absence of glucose. Inhibition of CD98 reduces the metabolic flexibility of this population, which may limit their pathogenic capacity. CD98
+ LDN produce more proinflammatory cytokines and chemokines than their normal density counterparts and are resistant to apoptosis, which may also contribute to tissue inflammation and end organ damage in SLE., Conclusions: CD98 provides a phenotypic marker for LDN that facilitates identification of this population without density-gradient separation and represents a novel therapeutic target to limit its pathogenic capacity., (© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.)- Published
- 2023
- Full Text
- View/download PDF
21. G-CSF Receptor Deletion Amplifies Cortical Bone Dysfunction in Mice With STAT3 Hyperactivation in Osteocytes.
- Author
-
Isojima T, Walker EC, Poulton IJ, McGregor NE, Wicks IP, Gooi JH, Martin TJ, and Sims NA
- Subjects
- Animals, Female, Male, Mice, Cortical Bone diagnostic imaging, Interleukin-6, RNA, Messenger, Granulocyte Colony-Stimulating Factor genetics, Osteocytes pathology, Receptors, Granulocyte Colony-Stimulating Factor, STAT3 Transcription Factor metabolism
- Abstract
Bone strength is determined by the structure and composition of its thickened outer shell (cortical bone), yet the mechanisms controlling cortical consolidation are poorly understood. Cortical bone maturation depends on SOCS3-mediated suppression of IL-6 cytokine-induced STAT3 phosphorylation in osteocytes, the cellular network embedded in bone matrix. Because SOCS3 also suppresses granulocyte-colony-stimulating factor receptor (G-CSFR) signaling, we here tested whether global G-CSFR (Csf3r) ablation altereed bone structure in male and female mice lacking SOCS3 in osteocytes, (Dmp1
Cre :Socs3f/f mice). Dmp1Cre :Socs3f/f :Csf3r-/- mice were generated by crossing Dmp1Cre :Socs3f/f mice with Csf3r-/- mice. Although G-CSFR is not expressed in osteocytes, Csf3r deletion further delayed cortical consolidation in Dmp1Cre :Socs3f/f mice. Micro-CT images revealed extensive, highly porous low-density bone, with little true cortex in the diaphysis, even at 26 weeks of age; including more low-density bone and less high-density bone in Dmp1Cre :Socs3f/f :Csf3r-/- mice than controls. By histology, the area where cortical bone would normally be found contained immature compressed trabecular bone in Dmp1Cre :Socs3f/f :Csf3r-/- mice and greater than normal levels of intracortical osteoclasts, extensive new woven bone formation, and the presence of more intracortical blood vessels than the already high levels observed in Dmp1Cre :Socs3f/f controls. qRT-PCR of cortical bone from Dmp1Cre :Socs3f/f :Csf3r-/- mice also showed more than a doubling of mRNA levels for osteoclasts, osteoblasts, RANKL, and angiogenesis markers. The further delay in cortical bone maturation was associated with significantly more phospho-STAT1 and phospho-STAT3-positive osteocytes, and a threefold increase in STAT1 and STAT3 target gene mRNA levels, suggesting G-CSFR deletion further increases STAT signaling beyond that of Dmp1Cre :Socs3f/f bone. G-CSFR deficiency therefore promotes STAT1/3 signaling in osteocytes, and when SOCS3 negative feedback is absent, elevated local angiogenesis, bone resorption, and bone formation delays cortical bone consolidation. This points to a critical role of G-CSF in replacing condensed trabecular bone with lamellar bone during cortical bone formation. © 2022 American Society for Bone and Mineral Research (ASBMR)., (© 2022 American Society for Bone and Mineral Research (ASBMR).)- Published
- 2022
- Full Text
- View/download PDF
22. Intimal macrophages develop from circulating monocytes during vasculitis.
- Author
-
Stock AT, Parsons S, Sharma VJ, James F, Starkey G, D'Costa R, Gordon CL, and Wicks IP
- Abstract
Objective: Vasculitis is characterised by inflammation of the blood vessels. While all layers of the vessel can be affected, inflammation within the intimal layer can trigger thrombosis and arterial occlusion and is therefore of particular clinical concern. Given this pathological role, we have examined how intimal inflammation develops by exploring which (and how) macrophages come to populate this normally immune-privileged site during vasculitis., Methods: We have addressed this question for Kawasaki disease (KD), which is a type of vasculitis in children that typically involves the coronary arteries. We used confocal microscopy and flow cytometry to characterise the macrophages that populate the coronary artery intima in KD patient samples and in a mouse model of KD, and furthermore, have applied an adoptive transfer system to trace how these intimal macrophages develop., Results: In KD patients, intimal hyperplasia coincided with marked macrophage infiltration of the coronary artery intima. Phenotypic analysis revealed that these 'intimal macrophages' did not express markers of resident cardiac macrophages, such as Lyve-1, and instead, were uniformly positive for the chemokine receptor Ccr2, suggesting a monocytic lineage. In support of this origin, we show that circulating monocytes directly invade the intima via transluminal migration during established disease, coinciding with the activation of endothelial cells lining the coronary arteries., Conclusions: During KD, intimal macrophages develop from circulating monocytes that infiltrate the inflamed coronary artery intima by transluminal migration., Competing Interests: IPW has received funding from CSL and Med‐Immune for research on cytokine antagonists. The remaining authors declare no conflict of interest., (© 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
23. Targeting necroptosis in muscle fibers ameliorates inflammatory myopathies.
- Author
-
Kamiya M, Mizoguchi F, Kawahata K, Wang D, Nishibori M, Day J, Louis C, Wicks IP, Kohsaka H, and Yasuda S
- Subjects
- Animals, Antibodies, Neutralizing pharmacology, C-Reactive Protein administration & dosage, Fas Ligand Protein genetics, Fas Ligand Protein immunology, Female, Gene Expression Regulation, Granzymes genetics, Granzymes immunology, HMGB1 Protein genetics, HMGB1 Protein immunology, Humans, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Muscle Fibers, Skeletal immunology, Muscle Fibers, Skeletal pathology, Muscle Strength drug effects, Muscle Strength immunology, Muscle, Skeletal drug effects, Muscle, Skeletal immunology, Muscle, Skeletal pathology, Myositis chemically induced, Myositis genetics, Myositis immunology, Necroptosis genetics, Necroptosis immunology, Perforin genetics, Perforin immunology, Polymyositis immunology, Polymyositis pathology, Signal Transduction, T-Lymphocytes, Cytotoxic drug effects, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic pathology, HMGB1 Protein antagonists & inhibitors, Imidazoles pharmacology, Indoles pharmacology, Muscle Fibers, Skeletal drug effects, Myositis prevention & control, Necroptosis drug effects, Polymyositis genetics
- Abstract
Muscle cell death in polymyositis is induced by CD8
+ cytotoxic T lymphocytes. We hypothesized that the injured muscle fibers release pro-inflammatory molecules, which would further accelerate CD8+ cytotoxic T lymphocytes-induced muscle injury, and inhibition of the cell death of muscle fibers could be a novel therapeutic strategy to suppress both muscle injury and inflammation in polymyositis. Here, we show that the pattern of cell death of muscle fibers in polymyositis is FAS ligand-dependent necroptosis, while that of satellite cells and myoblasts is perforin 1/granzyme B-dependent apoptosis, using human muscle biopsy specimens of polymyositis patients and models of polymyositis in vitro and in vivo. Inhibition of necroptosis suppresses not only CD8+ cytotoxic T lymphocytes-induced cell death of myotubes but also the release of inflammatory molecules including HMGB1. Treatment with a necroptosis inhibitor or anti-HMGB1 antibodies ameliorates myositis-induced muscle weakness as well as muscle cell death and inflammation in the muscles. Thus, targeting necroptosis in muscle cells is a promising strategy for treating polymyositis providing an alternative to current therapies directed at leukocytes., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
24. Emerging roles for IL-11 in inflammatory diseases.
- Author
-
Fung KY, Louis C, Metcalfe RD, Kosasih CC, Wicks IP, Griffin MDW, and Putoczki TL
- Subjects
- Animals, Autoimmune Diseases metabolism, Humans, Inflammation metabolism, Interleukin-11 metabolism
- Abstract
Interleukin-11 (IL-11) is a cytokine that has been strongly implicated in the pathogenesis of fibrotic diseases and solid malignancies. Elevated IL-11 expression is also associated with several non-malignant inflammatory diseases where its function remains less well-characterized. Here, we summarize current literature surrounding the contribution of IL-11 to the pathogenesis of autoimmune inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, diabetes and systemic sclerosis, as well as other chronic inflammatory conditions such as periodontitis, asthma, chronic obstructive pulmonary disease, psoriasis and colitis., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Hydroxychloroquine inhibits the mitochondrial antioxidant system in activated T cells.
- Author
-
Kim ML, Hardy MY, Edgington-Mitchell LE, Ramarathinam SH, Chung SZ, Russell AK, Currie I, Sleebs BE, Purcell AW, Tye-Din JA, and Wicks IP
- Abstract
Although hydroxychloroquine (HCQ) has long been used to treat autoimmune diseases, its mechanism of action remains poorly understood. In CD4 T-cells, we found that a clinically relevant concentration of HCQ inhibited the mitochondrial antioxidant system triggered by TCR crosslinking, leading to increased mitochondrial superoxide, impaired activation-induced autophagic flux, and reduced proliferation of CD4 T-cells. In antigen-presenting cells, HCQ also reduced constitutive activation of the endo-lysosomal protease legumain and toll-like receptor 9, thereby reducing cytokine production, but it had little apparent impact on constitutive antigen processing and peptide presentation. HCQ's effects did not require endo-lysosomal pH change, nor impaired autophagosome-lysosome fusion. We explored the clinical relevance of these findings in patients with celiac disease-a prototypic CD4 T-cell-mediated disease-and found that HCQ limits ex vivo antigen-specific T cell responses. We report a T-cell-intrinsic immunomodulatory effect from HCQ and suggest potential re-purposing of HCQ for celiac disease., Competing Interests: J.T-D. and M.Y.H. are inventors of patents pertaining to the use of gluten-derived T cell epitopes for use in CeD therapeutics. A.W.P. is a scientific advisor for Bioinformatics Solutions Inc. (providers of PEAKS X Pro software). I.P.W. is a scientific advisor for CSL Pty Ltd. The other authors declare no competing interests. All remaining authors declare no competing interests., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
26. Differential requirement for the Polycomb repressor complex 2 in dendritic cell and tissue-resident myeloid cell homeostasis.
- Author
-
Zhan Y, Zhang Y, Zhang S, Coughlan H, Baldoni PL, Jacquelot N, Cao WHJ, Preston S, Louis C, Rautela J, Pellegrini M, Wicks IP, Alexander WS, Harrison LC, Lew AM, Smyth GK, Nutt SL, and Chopin M
- Subjects
- Animals, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Polycomb Repressive Complex 2 deficiency, Dendritic Cells immunology, Homeostasis immunology, Myeloid Cells immunology, Polycomb Repressive Complex 2 immunology
- Abstract
Dendritic cells (DCs) and macrophages are at the forefront of immune responses, modifying their transcriptional programs in response to their tissue environment or immunological challenge. Posttranslational modifications of histones, such as histone H3 lysine-27 trimethylation (H3K27me3) by the Polycomb repressive complex 2 (PRC2), are tightly associated with epigenetic regulation of gene expression. To explore whether H3K27me3 is involved in either the establishment or function of the mononuclear phagocyte system, we selectively deleted core components of PRC2, either EZH2 or SUZ12, in CD11c-expressing myeloid cells. Unexpectedly, EZH2 deficiency neither prevented the deposition and maintenance of H3K27me3 in DCs nor hindered DC/macrophage homeostasis. In contrast, SUZ12 deficiency markedly impaired the capacity of DCs and macrophages to maintain H3K27me3. SUZ12 ablation induced a rapid loss of the alveolar macrophage and Langerhans cell networks under both steady state and inflammatory conditions because these cells could no longer proliferate to facilitate their self-renewal. Despite the reduced H3K27me3, DC development and function were unaffected by SUZ12 ablation, suggesting that PRC2-mediated gene repression was dispensable for DC homeostasis. Thus, the role of SUZ12 highlights the fundamentally different homeostatic mechanisms used by tissue-resident myeloid cells versus DCs.
- Published
- 2021
- Full Text
- View/download PDF
27. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.
- Author
-
Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, Grisaru-Tal S, Louis C, Huang Q, Schreuder J, Souza-Fonseca-Guimaraes F, de Graaf CA, Thia K, Macdonald S, Camilleri M, Luong K, Zhang S, Chopin M, Molden-Hauer T, Nutt SL, Umansky V, Ciric B, Groom JR, Foster PS, Hansbro PM, McKenzie ANJ, Gray DHD, Behren A, Cebon J, Vivier E, Wicks IP, Trapani JA, Munitz A, Davis MJ, Shi W, Neeson PJ, and Belz GT
- Subjects
- Animals, Cell Line, Tumor, Chemotaxis, Leukocyte drug effects, Cytotoxicity, Immunologic drug effects, Eosinophils drug effects, Eosinophils immunology, Eosinophils metabolism, Female, Granulocyte-Macrophage Colony-Stimulating Factor genetics, Granulocyte-Macrophage Colony-Stimulating Factor metabolism, Humans, Lymphocytes immunology, Lymphocytes metabolism, Male, Melanoma, Experimental genetics, Melanoma, Experimental immunology, Melanoma, Experimental metabolism, Mice, Inbred C57BL, Mice, Knockout, Phenotype, Programmed Cell Death 1 Receptor genetics, Programmed Cell Death 1 Receptor metabolism, Skin Neoplasms genetics, Skin Neoplasms immunology, Skin Neoplasms metabolism, Mice, Antibodies pharmacology, Antineoplastic Combined Chemotherapy Protocols pharmacology, Immune Checkpoint Inhibitors pharmacology, Interleukin-33 pharmacology, Lymphocytes drug effects, Melanoma, Experimental drug therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors, Skin Neoplasms drug therapy
- Abstract
Group 2 innate lymphoid cells (ILC2s) are essential to maintain tissue homeostasis. In cancer, ILC2s can harbor both pro-tumorigenic and anti-tumorigenic functions, but we know little about their underlying mechanisms or whether they could be clinically relevant or targeted to improve patient outcomes. Here, we found that high ILC2 infiltration in human melanoma was associated with a good clinical prognosis. ILC2s are critical producers of the cytokine granulocyte-macrophage colony-stimulating factor, which coordinates the recruitment and activation of eosinophils to enhance antitumor responses. Tumor-infiltrating ILC2s expressed programmed cell death protein-1, which limited their intratumoral accumulation, proliferation and antitumor effector functions. This inhibition could be overcome in vivo by combining interleukin-33-driven ILC2 activation with programmed cell death protein-1 blockade to significantly increase antitumor responses. Together, our results identified ILC2s as a critical immune cell type involved in melanoma immunity and revealed a potential synergistic approach to harness ILC2 function for antitumor immunotherapies.
- Published
- 2021
- Full Text
- View/download PDF
28. BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia.
- Author
-
Carrington EM, Louis C, Kratina T, Hancock M, Keenan CR, Iannarella N, Allan RS, Wardak AZ, Czabotar PE, Herold MJ, Schenk RL, White CA, D'Silva D, Yang Y, Wong W, Wong H, Bryant VL, Huntington ND, Rautela J, Sutherland RM, Zhan Y, Hansen J, Nhu D, Lessene G, Wicks IP, and Lew AM
- Subjects
- Animals, Apoptosis, Longevity, Mice, Neutropenia drug therapy, Neutrophils
- Abstract
Neutrophils help to clear pathogens and cellular debris, but can also cause collateral damage within inflamed tissues. Prolonged neutrophil residency within an inflammatory niche can exacerbate tissue pathology. Using both genetic and pharmacological approaches, we show that BCL-XL is required for the persistence of neutrophils within inflammatory sites in mice. We demonstrate that a selective BCL-XL inhibitor (A-1331852) has therapeutic potential by causing apoptosis in inflammatory human neutrophils ex vivo. Moreover, in murine models of acute and chronic inflammatory disease, it reduced inflammatory neutrophil numbers and ameliorated tissue pathology. In contrast, there was minimal effect on circulating neutrophils. Thus, we show a differential survival requirement in activated neutrophils for BCL-XL and reveal a new therapeutic approach to neutrophil-mediated diseases., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
29. Extracellular Vesicles in Synovial Fluid from Rheumatoid Arthritis Patients Contain miRNAs with Capacity to Modulate Inflammation.
- Author
-
Foers AD, Garnham AL, Chatfield S, Smyth GK, Cheng L, Hill AF, Wicks IP, and Pang KC
- Subjects
- Aged, Arthritis, Rheumatoid complications, Cohort Studies, Extracellular Vesicles ultrastructure, Female, Gene Expression Profiling, Gene Expression Regulation, Humans, Immunologic Factors metabolism, Inflammation complications, Inflammation pathology, Male, MicroRNAs metabolism, Middle Aged, Arthritis, Rheumatoid genetics, Extracellular Vesicles genetics, Inflammation genetics, MicroRNAs genetics, Synovial Fluid metabolism
- Abstract
In rheumatoid arthritis (RA), extracellular vesicles (EVs) are associated with both the propagation and attenuation of joint inflammation and destruction. However, the specific EV content responsible for these processes is largely unknown. Investigations into identifying EV content are confounded by the challenges in obtaining high-quality EV preparations from synovial fluid. Implementing a size exclusion chromatography-based method of EV isolation, coupled with small RNA sequencing, we accurately characterised EV miRNAs in synovial fluid obtained from RA patients and investigated the differences between joints with high- and low-grade inflammation. Synovial fluid was obtained from the joints of 12 RA patients and, based on leukocyte counts, classified as either high ( n = 7)- or low ( n = 5)-grade inflammation. Using size exclusion chromatography, EVs were purified and small RNA was extracted and sequenced on a NextSeq 500. Sequencing reads were aligned to miRBase v21, and differences in miRNA profiles between RA patients with high- and low-grade joint inflammation were analysed. In total, 1972 distinct miRNAs were identified from RA synovial fluid EVs. miRNAs with less than five reads in fewer than five patients were filtered out, leaving 318 miRNAs for analysis. Analysis of the most abundant miRNAs suggested that they negatively regulate multiple genes relevant to inflammation, including signal transducer and activator of transcription 3 (STAT3), which lies downstream of IL-6 and has a pro-inflammatory role in RA. Synovial fluid from joints with high-grade inflammation contained 3.5-fold more EV miRNA per mL of synovial fluid ( p = 0.0017). Seventy-eight EV miRNAs were differentially expressed between RA joints with high- and low-grade inflammation, and pathway analysis revealed that their target genes were commonly involved a variety of processes, including cellular apoptosis, proliferation and migration. Of the 49 miRNAs that were elevated in joints with high-grade inflammation, pathway analysis revealed that genes involved in cytokine-mediated signalling pathways were significantly enriched targets. In contrast, genes associated with reactive oxygen species signalling were significantly enriched as targets of the 29 miRNAs elevated in joints with low-grade inflammation. Our study identified an abundance of EV miRNAs from the synovial fluid of RA patients with the potential to modulate inflammation. In doing so, we defined potential mechanisms by which synovial fluid EVs may contribute to RA pathophysiology.
- Published
- 2021
- Full Text
- View/download PDF
30. G-CSF - A double edge sword in neutrophil mediated immunity.
- Author
-
Martin KR, Wong HL, Witko-Sarsat V, and Wicks IP
- Subjects
- Animals, Bone Marrow metabolism, Cell Differentiation, Humans, Inflammation metabolism, Mice, Granulocyte Colony-Stimulating Factor metabolism, Neutrophils
- Abstract
Neutrophils are vital for the innate immune system's control of pathogens and neutrophil deficiency can render the host susceptible to life-threatening infections. Neutrophil responses must also be tightly regulated because excessive production, recruitment or activation of neutrophils can cause tissue damage in both acute and chronic inflammatory diseases. Granulocyte colony stimulating factor (G-CSF) is a key regulator of neutrophil biology, from production, differentiation, and release of neutrophil precursors in the bone marrow (BM) to modulating the function of mature neutrophils outside of the BM, particularly at sites of inflammation. G-CSF acts by binding to its cognate cell surface receptor on target cells, causing the activation of intracellular signalling pathways mediating the proliferation, differentiation, function, and survival of cells in the neutrophil lineage. Studies in humans and mice demonstrate that G-CSF contributes to protecting the host against infection, but conversely, it can play a deleterious role in inflammatory diseases. As such, neutrophils and the G-CSF pathway may provide novel therapeutic targets. This review will focus on understanding the role G-CSF plays in the balance between effective neutrophil mediated host defence versus neutrophil-mediated inflammation and tissue damage in various inflammatory and infectious diseases., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
31. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'.
- Author
-
Nikpour M, Teh B, Wicks IP, and Pellegrini M
- Subjects
- Humans, Hydroxychloroquine therapeutic use, Coronavirus, Coronavirus Infections complications, Coronavirus Infections drug therapy, Lupus Erythematosus, Systemic chemically induced, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic drug therapy, COVID-19 Drug Treatment
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2021
- Full Text
- View/download PDF
32. Natural killer cells in inflammatory autoimmune diseases.
- Author
-
Yang Y, Day J, Souza-Fonseca Guimaraes F, Wicks IP, and Louis C
- Abstract
Natural killer (NK) cells are a specialised population of innate lymphoid cells (ILCs) that help control local immune responses. Through natural cytotoxicity, production of cytokines and chemokines, and migratory capacity, NK cells play a vital immunoregulatory role in the initiation and chronicity of inflammatory and autoimmune responses. Our understanding of their functional differences and contributions in disease settings is evolving owing to new genetic and functional murine proof-of-concept studies. Here, we summarise current understanding of NK cells in several classic autoimmune disorders, particularly in rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE) and type 1 diabetes mellitus (T1DM), but also less understood diseases such as idiopathic inflammatory myopathies (IIMs). A better understanding of how NK cells contribute to these autoimmune disorders may pave the way for NK cell-targeted therapeutics., Competing Interests: FSFG is a consultant for Biotheus Inc., (© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
33. Circulating Small Noncoding RNA Biomarkers of Response to Triple Disease-modifying Antirheumatic Drug Therapy in White Women With Early Rheumatoid Arthritis.
- Author
-
Foers AD, Garnham AL, Smyth GK, Proudman SM, Cheng L, Hill AF, Pang KC, and Wicks IP
- Subjects
- Biomarkers, Drug Therapy, Combination, Female, Humans, Methotrexate therapeutic use, Sulfasalazine therapeutic use, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, RNA, Small Untranslated therapeutic use
- Abstract
Objective: To identify small noncoding RNA (sncRNA) serum biomarkers that predict response to triple disease-modifying antirheumatic drug (DMARD) therapy in patients with early rheumatoid arthritis (RA)., Methods: Early RA patients entered into a treat-to-target management algorithm, with triple DMARD therapy (methotrexate, sulfasalazine, hydroxychloroquine). Patients were assessed following 6 months of therapy and classified as European League Against Rheumatism responders or nonresponders. RNA was isolated from 42 archived serum samples, collected prior to commencement of triple DMARD therapy. Small RNA sequencing was performed and the reads mapped to annotations in a database of human sncRNA. Differential expression analysis was performed, comparing responders (n = 24) and nonresponders (n = 18)., Results: Pretreatment levels of 4 sncRNA were significantly increased in nonresponders: chr1. tRNA131-GlyCCC (4.1-fold, adjusted P = 0.01), chr2.tRNA13-AlaCGC (2.2-fold, adjusted P = 0.02), U2-L166 (6.6-fold, adjusted P = 0.02), and piR-35982 (2.4-fold, adjusted P = 0.03). 5S-L612 was the only sncRNA significantly increased in responders (3.3-fold; adjusted P = 0.01). Reads for chr1. tRNA131-GlyCCC and chr2.tRNA13-AlaCGC mapped to the 5' end of each tRNA gene and were truncated at the anticodon loop, consistent with these sncRNA having roles as 5' translation interfering tRNA halves (tiRNA)., Conclusion: Pretreatment levels of specific serum sncRNA might facilitate identification of patients more likely to respond to triple DMARD therapy.
- Published
- 2020
- Full Text
- View/download PDF
34. Inhibition of interleukin-1β signalling promotes atherosclerotic lesion remodelling in mice with inflammatory arthritis.
- Author
-
Dragoljevic D, Lee MKS, Louis C, Shihata W, Kraakman MJ, Hansen J, Masters SL, Hanaoka BY, Nagareddy PR, Lancaster GI, Wicks IP, and Murphy AJ
- Abstract
Objectives: Rheumatoid arthritis (RA), an inflammatory joint disorder, independently increases the risk of cardiovascular disease (CVD). IL-1β contributes to both RA and CVD. We hypothesised that inhibiting IL-1 signalling with the IL-1R antagonist, anakinra, would dampen inflammation and promote resolution of atherosclerosis in arthritic mice., Methods: Low-density lipoprotein receptor (Ldlr)-deficient mice were fed a Western-type diet for 14 weeks to develop atherosclerotic plaques. Mice were then switched to a chow diet, promoting lesion regression, and randomised to a control group or into groups where arthritis was induced by passive transfer of K/BxN arthritogenic serum. The arthritic mice were further randomised to vehicle or anakinra., Results: Arthritis impaired atherosclerotic lesion regression when cholesterol was lowered. This was associated with a higher burden of plaque macrophages, likely due to monocytosis, driven by myelopoiesis in the bone marrow and spleen. Interestingly, delayed intervention with anakinra had no effect on arthritis in these mice. However, a significant improvement in atherosclerotic plaque remodelling to a more stable phenotype was observed. This was associated with fewer circulating monocytes, caused by a reduction in splenic extramedullary myelopoiesis., Conclusion: We show that inhibiting IL-1 signalling in arthritic mice with pre-existing atherosclerosis promotes lesion remodelling to a more stable phenotype, that is less likely to rupture and cause ischemic events such as myocardial infarction. This suggests that IL-1R antagonism may suppress CVD complications in patients with RA. Furthermore, inhibiting IL-1β signalling in other patients with inflammatory diseases that also predispose to CVD may also benefit from anti-IL-1 therapy., Competing Interests: The authors declare no conflict of interest., (© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
35. Proteomic analysis of extracellular vesicles reveals an immunogenic cargo in rheumatoid arthritis synovial fluid.
- Author
-
Foers AD, Dagley LF, Chatfield S, Webb AI, Cheng L, Hill AF, Wicks IP, and Pang KC
- Abstract
Objectives: Extracellular vesicles (EVs) from rheumatoid arthritis (RA) synovial fluid (SF) have been reported to stimulate the release of pro-inflammatory mediators from recipient cells. We recently developed a size exclusion chromatography (SEC)-based method for EV isolation capable of high-quality enrichments from human SF. Here, we employed this method to accurately characterise the SF EV proteome and investigate potential contributions to inflammatory pathways in RA., Methods: Using our SEC-based approach, SF EVs were purified from the joints of RA patients classified as having high-level ( n = 7) or low-level inflammation ( n = 5), and from osteoarthritis (OA) patients ( n = 5). Protein profiles were characterised by mass spectrometry. Potential contributions of EV proteins to pathological pathways and differences in protein expression between disease groups were investigated., Results: Synovial fluid EVs were present at higher concentrations in RA joints with high-level inflammation ( P- value = 0.004) but were smaller in diameter ( P- value = 0.03) than in low-level inflammation. In total, 1058 SF EV proteins were identified by mass spectrometry analysis. Neutrophil and fibroblast markers were overrepresented in all disease groups. Numerous proteins with potential to modulate inflammatory and immunological processes were detected, including nine citrullinated peptides. Forty-five and 135 EV-associated proteins were significantly elevated in RA joints with high-level inflammation than in RA joints with low-level inflammation and OA joints, respectively. Gene ontology analysis revealed significant enrichment for proteins associated with 'neutrophil degranulation' within SF EVs from RA joints with high-level inflammation., Conclusion: Our results provide new information about SF EVs and insight into how EVs might contribute to the perpetuation of RA., Competing Interests: The authors declare no conflict of interest., (© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
36. Inflammasomes and Cell Death: Common Pathways in Microparticle Diseases.
- Author
-
Rashidi M, Wicks IP, and Vince JE
- Subjects
- Animals, Cell Communication drug effects, Cell-Derived Microparticles metabolism, Cellular Microenvironment, Disease Susceptibility etiology, Disease Susceptibility metabolism, Humans, Interleukin-1beta metabolism, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Pyroptosis, Signal Transduction drug effects, Cell Death, Inflammasomes metabolism
- Abstract
The accumulation of cellular and environmental microparticles has been linked to many diseases associated with tissue inflammation. These particulate-driven diseases include joint, lung, kidney, cardiovascular, and neurodegenerative disorders. Recently a conserved proinflammatory inflammasome signaling pathway elicited by such microparticles has become apparent. Here, we review disease-promoting microparticles and the mechanisms by which they trigger activation of the inflammasome complexes responsible for generating bioactive interleukin-1β (IL-1β) and inducing cell death. We highlight how microparticle-induced inflammasome and cell death responses diverge from canonical inflammasome activators, and discuss the preclinical and clinical targeting of inflammasomes to treat microparticle-driven diseases., (Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
37. Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease.
- Author
-
Anderton H, Wicks IP, and Silke J
- Subjects
- Animals, Antibodies, Monoclonal, Humanized therapeutic use, Apoptosis genetics, Cell Death drug effects, Chemokines metabolism, Chronic Disease, Cytokines metabolism, Extracellular Traps metabolism, Humans, Immunity, Innate immunology, Immunologic Factors therapeutic use, Mice, Models, Animal, Necroptosis genetics, Pyroptosis genetics, Rheumatic Diseases pathology, Signal Transduction drug effects, Alarmins metabolism, Cell Death immunology, Homeostasis immunology, Inflammation immunology, Rheumatic Diseases drug therapy
- Abstract
Cell death is a vital process that occurs in billions of cells in the human body every day. This process helps maintain tissue homeostasis, supports recovery from acute injury, deals with infection and regulates immunity. Cell death can also provoke inflammatory responses, and lytic forms of cell death can incite inflammation. Loss of cell membrane integrity leads to the uncontrolled release of damage-associated molecular patterns (DAMPs), which are normally sequestered inside cells. Such DAMPs increase local inflammation and promote the production of cytokines and chemokines that modulate the innate immune response. Cell death can be both a consequence and a cause of inflammation, which can be difficult to distinguish in chronic diseases. Despite this caveat, excessive or poorly regulated cell death is increasingly recognized as a contributor to chronic inflammation in rheumatic disease and other inflammatory conditions. Drugs that inhibit cell death could, therefore, be used therapeutically for the treatment of these diseases, and programmes to develop such inhibitors are already underway. In this Review, we outline pathways for the major cell death programmes (apoptosis, necroptosis, pyroptosis and NETosis) and their potential roles in chronic inflammation. We also discuss current and developing therapies that target the cell death machinery.
- Published
- 2020
- Full Text
- View/download PDF
38. Leukocyte Tetraspanin CD53 Restrains α 3 Integrin Mobilization and Facilitates Cytoskeletal Remodeling and Transmigration in Mice.
- Author
-
Yeung L, Anderson JML, Wee JL, Demaria MC, Finsterbusch M, Liu YS, Hall P, Smith BC, Dankers W, Elgass KD, Wicks IP, Kwok HF, Wright MD, and Hickey MJ
- Subjects
- Animals, Chemokine CCL2 metabolism, Chemokine CXCL1 metabolism, Humans, Mice, Mice, Inbred C57BL, Mice, Knockout, Transendothelial and Transepithelial Migration, Arthritis, Experimental immunology, Arthritis, Rheumatoid immunology, Cytoskeleton metabolism, Integrin alpha3 metabolism, L-Selectin metabolism, Neutrophils physiology, Tetraspanin 25 metabolism
- Abstract
The importance of tetraspanin proteins in regulating migration has been demonstrated in many diverse cellular systems. However, the function of the leukocyte-restricted tetraspanin CD53 remains obscure. We therefore hypothesized that CD53 plays a role in regulating leukocyte recruitment and tested this hypothesis by examining responses of CD53-deficient mice to a range of inflammatory stimuli. Deletion of CD53 significantly reduced neutrophil recruitment to the acutely inflamed peritoneal cavity. Intravital microscopy revealed that in response to several inflammatory and chemotactic stimuli, absence of CD53 had only minor effects on leukocyte rolling and adhesion in postcapillary venules. In contrast, Cd53
-/- mice showed a defect in leukocyte transmigration induced by TNF, CXCL1 and CCL2, and a reduced capacity for leukocyte retention on the endothelial surface under shear flow. Comparison of adhesion molecule expression in wild-type and Cd53-/- neutrophils revealed no alteration in expression of β2 integrins, whereas L-selectin was almost completely absent from Cd53-/- neutrophils. In addition, Cd53-/- neutrophils showed defects in activation-induced cytoskeletal remodeling and translocation to the cell periphery, responses necessary for efficient transendothelial migration, as well as increased α3 integrin expression. These alterations were associated with effects on inflammation, so that in Cd53-/- mice, the onset of neutrophil-dependent serum-induced arthritis was delayed. Together, these findings demonstrate a role for tetraspanin CD53 in promotion of neutrophil transendothelial migration and inflammation, associated with CD53-mediated regulation of L-selectin expression, attachment to the endothelial surface, integrin expression and trafficking, and cytoskeletal function., (Copyright © 2020 by The American Association of Immunologists, Inc.)- Published
- 2020
- Full Text
- View/download PDF
39. NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS.
- Author
-
Louis C, Souza-Fonseca-Guimaraes F, Yang Y, D'Silva D, Kratina T, Dagley L, Hediyeh-Zadeh S, Rautela J, Masters SL, Davis MJ, Babon JJ, Ciric B, Vivier E, Alexander WS, Huntington ND, and Wicks IP
- Subjects
- Animals, Arthritis, Rheumatoid immunology, Autoantibodies, Female, Humans, Inflammation immunology, Interleukin-18 metabolism, Janus Kinase 2 metabolism, Male, Mice, Inbred C57BL, Myeloid Cells metabolism, Neutrophils metabolism, STAT5 Transcription Factor metabolism, Signal Transduction, Synovial Fluid metabolism, Synovial Membrane metabolism, Synovial Membrane pathology, Arthritis, Rheumatoid pathology, Granulocyte-Macrophage Colony-Stimulating Factor metabolism, Inflammation pathology, Killer Cells, Natural metabolism, Suppressor of Cytokine Signaling Proteins metabolism
- Abstract
Despite increasing recognition of the importance of GM-CSF in autoimmune disease, it remains unclear how GM-CSF is regulated at sites of tissue inflammation. Using GM-CSF fate reporter mice, we show that synovial NK cells produce GM-CSF in autoantibody-mediated inflammatory arthritis. Synovial NK cells promote a neutrophilic inflammatory cell infiltrate, and persistent arthritis, via GM-CSF production, as deletion of NK cells, or specific ablation of GM-CSF production in NK cells, abrogated disease. Synovial NK cell production of GM-CSF is IL-18-dependent. Furthermore, we show that cytokine-inducible SH2-containing protein (CIS) is crucial in limiting GM-CSF signaling not only during inflammatory arthritis but also in experimental allergic encephalomyelitis (EAE), a murine model of multiple sclerosis. Thus, a cellular cascade of synovial macrophages, NK cells, and neutrophils mediates persistent joint inflammation via production of IL-18 and GM-CSF. Endogenous CIS provides a key brake on signaling through the GM-CSF receptor. These findings shed new light on GM-CSF biology in sterile tissue inflammation and identify several potential therapeutic targets., Competing Interests: Disclosures: Dr. Rautela is the co-founder and CEO of oNKo-innate Pty. Ltd. Dr. Masters reported personal fees from IFM Therapeutics, personal fees from Quench Bio, and grants from GlaxoSmithKline outside the submitted work. Dr. Babon reported a patent to inhibition of cytokine-induced sh2 protein in NK cells, licensed "Servier." Dr. Vivier reported personal fees from Innate Pharma during the conduct of the study; personal fees from Innate Pharma outside the submitted work; and is an employee of Innate Pharma. Dr. Huntington reported "other" from Servier during the conduct of the study; personal fees from ONKo-Innate outside the submitted work; has a patent to WO201700861A1 with royalties paid, Servier; and is the founder of oNKo-Innate Pty Ltd. Dr. Wicks reported, "I have argued that GM-CSF is an important therapeutic target in inflammatory diseases (see Wicks and Roberts, Nature Reviews Rheumatology 2016) and have provided advice around clinical translation to several companies interested in the area, namely Medimmune and Kiniksa. I have no relevant IP and these companies were not involved in the project described in our submission to JEM, nor did they provide funding. I don't believe there is any conflict of interest, but declare it because I have been an advocate for therapeutic antagonism of GM-CSF." No other disclosures were reported., (© 2020 Louis et al.)
- Published
- 2020
- Full Text
- View/download PDF
40. Correction: NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS.
- Author
-
Louis C, Souza-Fonseca-Guimaraes F, Yang Y, D'Silva D, Kratina T, Dagley L, Hediyeh-Zadeh S, Rautela J, Masters SL, Davis MJ, Babon JJ, Ciric B, Vivier E, Alexander WS, Huntington ND, and Wicks IP
- Published
- 2020
- Full Text
- View/download PDF
41. TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells.
- Author
-
Balka KR, Louis C, Saunders TL, Smith AM, Calleja DJ, D'Silva DB, Moghaddas F, Tailler M, Lawlor KE, Zhan Y, Burns CJ, Wicks IP, Miner JJ, Kile BT, Masters SL, and De Nardo D
- Subjects
- Animals, Female, HEK293 Cells, Humans, I-kappa B Kinase physiology, Immunity, Innate, Interferon Regulatory Factor-3 metabolism, Interferon-beta metabolism, Male, Membrane Proteins metabolism, Membrane Proteins physiology, Mice, Mice, Inbred C57BL, Myeloid Cells metabolism, NF-kappa B metabolism, Nucleotides, Cyclic metabolism, Phosphorylation, Protein Serine-Threonine Kinases physiology, Signal Transduction immunology, I-kappa B Kinase metabolism, Protein Serine-Threonine Kinases metabolism
- Abstract
Stimulator of Interferon Genes (STING) is a critical component of host innate immune defense but can contribute to chronic autoimmune or autoinflammatory disease. Once activated, the cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) (cGAMP) synthase (cGAS)-STING pathway induces both type I interferon (IFN) expression and nuclear factor-κB (NF-κB)-mediated cytokine production. Currently, these two signaling arms are thought to be mediated by a single upstream kinase, TANK-binding kinase 1 (TBK1). Here, using genetic and pharmacological approaches, we show that TBK1 alone is dispensable for STING-induced NF-κB responses in human and mouse immune cells, as well as in vivo. We further demonstrate that TBK1 acts redundantly with IκB kinase ε (IKKε) to drive NF-κB upon STING activation. Interestingly, we show that activation of IFN regulatory factor 3 (IRF3) is highly dependent on TBK1 kinase activity, whereas NF-κB is significantly less sensitive to TBK1/IKKε kinase inhibition. Our work redefines signaling events downstream of cGAS-STING. Our findings further suggest that cGAS-STING will need to be targeted directly to effectively ameliorate the inflammation underpinning disorders associated with STING hyperactivity., Competing Interests: Declaration of Interests S.L.M. receives funding from GlaxoSmithKline., (Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
42. A potential association between IL-3 and type I and III interferons in systemic lupus erythematosus.
- Author
-
Oon S, Monaghan K, Ng M, Hoi A, Morand E, Vairo G, Maraskovsky E, Nash AD, Wicks IP, and Wilson NJ
- Abstract
Objectives: Plasmacytoid dendritic cells (pDCs), through the production of type 1 interferons (IFNs) and other cytokines, are major contributors to systemic lupus erythematosus (SLE) pathogenesis. IL-3 promotes pDC survival, but its role in SLE is not well characterised. This study investigated serum IL-3 and IFN levels, and a whole blood 'IL-3 gene signature', in human SLE., Methods: Serum cytokine levels were measured by ELISA in n = 42 SLE patients, and n = 44 healthy donors. IL-3-regulated genes were determined by RNASeq of healthy donor whole blood cells (WBCs) stimulated in vitro with IL-3 for 6 or 24 h. Whole blood cell RNASeq analysis was undertaken in a separate cohort of n = 31 SLE patients, and n = 28 healthy donors., Results: Serum IL-3 levels correlated with IFNα ( r = 0.612, 95% CI 0.455-0.733, P < 0.001) and type III IFN ( r = 0.585, 95% CI 0.406-0.720, P < 0.0001). IL-3 stimulation of WBC in vitro altered 794 genes (-1 ≥ logFC ≥ 1, FDR < 0.05), of which 35 overlapped with genes differentially expressed between SLE and healthy donors. These 35 genes were expressed in 27/31 SLE donors, revealing the presence of an 'IL-3 gene signature'. There was strong correlation between the IL-3 signature and an IFN signature, as determined by hierarchical clustering of the 500 most variable genes in SLE donors ( r = 0.939, 95% CI 0.898-0.964, P < 0.0001)., Conclusion: A dual IL-3/IFN gene signature is a feature of SLE. An association between IL-3 and IFN raises the possibility that dual blockade of IL-3 and IFN may be especially useful for SLE patients with this dual cytokine gene signature., Competing Interests: SO, IPW, AH and EM have received research funding from CSL Limited. KM, MN, GV, EM, ADN and NJW are employees of CSL Limited, and KM, GV, EM, ADN and NJW hold stock in CSL Limited., (© 2019 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.)
- Published
- 2019
- Full Text
- View/download PDF
43. The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy.
- Author
-
Boulos D, Proudman SM, Metcalf RG, McWilliams L, Hall C, and Wicks IP
- Subjects
- Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid blood, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Prognosis, Treatment Failure, Arthritis, Rheumatoid drug therapy, Hydroxychloroquine therapeutic use, Lymphocytes pathology, Methotrexate therapeutic use, Neutrophils pathology, Sulfasalazine therapeutic use
- Abstract
Objectives: To assess whether the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can predict those who subsequently require escalation of disease modifying therapy because of continued disease activity in rheumatoid arthritis (RA)., Methods: Patients with newly diagnosed RA were recruited from the Early Arthritis Clinic at the Royal Adelaide Hospital. All patients commenced "triple-therapy" with a standardised protocol of methotrexate, sulfasalazine and hydroxychloroquine, and were reviewed every three to six weeks. DMARD therapy was adjusted according to a pre-defined algorithm if not in low disease activity. The NLR, PLR and other markers of disease activity including ESR, CRP and DAS28 were collected, as well as current therapy. The primary outcome measure was failure of triple-therapy to maintain low-disease activity (DAS28<3.2) at 12 months., Results: Two-hundred and twenty-two patients met inclusion criteria. The mean age was 54.2 ± 15.4 years, with a mean disease duration of 22.3 ± 25.0 weeks. Forty-five (20%) patients had failed triple therapy by one year. The mean baseline NLR was significantly higher in those who failed triple therapy compared with those who did not (3.7 ± 2.8 vs. 2.9 ± 1.5; p = 0.02), however, the PLR was not significantly different. A baseline NLR>2.7 was an independent predictor of treatment failure (OR 2.65, CI 1.23-5.72, p = 0.01) whilst the PLR, ESR, CRP and DAS-28ESR were not., Conclusion: The NLR is significantly increased in those who subsequently fail triple-therapy for RA, and it outperformed conventional markers of disease activity. The NLR may offer an inexpensive, objective and reproducible prognostic marker in RA. Further studies are justified to confirm its potential role in guiding the management of RA., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
44. SIDT2 RNA Transporter Promotes Lung and Gastrointestinal Tumor Development.
- Author
-
Nguyen TA, Bieging-Rolett KT, Putoczki TL, Wicks IP, Attardi LD, and Pang KC
- Abstract
RNautophagy is a newly described type of selective autophagy whereby cellular RNAs are transported into lysosomes for degradation. This process involves the transmembrane protein SIDT2, which transports double-stranded RNA (dsRNA) across the endolysosomal membrane. We previously demonstrated that SIDT2 is a transcriptional target of p53, but its role in tumorigenesis, if any, is unclear. Unexpectedly, we show here that Sidt2
-/- mice with concurrent oncogenic KrasG12D activation develop significantly fewer tumors than littermate controls in a mouse model of lung adenocarcinoma. Consistent with this observation, loss of SIDT2 also leads to enhanced survival and delayed tumor development in an Apcmin/+ mouse model of intestinal cancer. Within the intestine, Apcmin/+ ;Sidt2-/- mice display accumulation of dsRNA in association with increased phosphorylation of eIF2α and JNK as well as elevated rates of apoptosis. Taken together, our data demonstrate a role for SIDT2, and by extension RNautophagy, in promoting tumor development., (Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
45. Deleting Suppressor of Cytokine Signaling-3 in chondrocytes reduces bone growth by disrupting mitogen-activated protein kinase signaling.
- Author
-
Liu X, D'Cruz AA, Hansen J, Croker BA, Lawlor KE, Sims NA, and Wicks IP
- Subjects
- Animals, Female, Male, Mice, Mice, Transgenic, Signal Transduction, Bone Development physiology, Chondrocytes physiology, Mitogen-Activated Protein Kinases physiology, Suppressor of Cytokine Signaling 1 Protein physiology
- Abstract
Objective: To investigate the impact of deleting Suppressor of Cytokine Signaling (SOCS)-3 (SOCS3) in chondrocytes during murine skeletal development., Method: Mice with a conditional Socs3 allele (Socs3
fl/fl ) were crossed with a transgenic mouse expressing Cre recombinase under the control of the type II collagen promoter (Col2a1) to generate Socs3Δ/Δcol2 mice. Skeletal growth was analyzed over the lifespan of Socs3Δ/Δcol2 mice and controls by detailed histomorphology. Bone size and cortical bone development was evaluated by micro-computed tomography (micro-CT). Growth plate (GP) zone width, chondrocyte proliferation and apoptosis were assessed by immunofluorescence staining for Ki67 and TUNEL. Fibroblast growth factor receptor-3 (FGFR3) signaling in the GP was assessed by immunohistochemistry, while the effect of SOCS3 overexpression on FGFR3-driven pMAPK signaling in HEK293T cells was evaluated by Western blot., Results: Socs3Δ/Δcol2 mice of both sexes were consistently smaller compared to littermate controls throughout life. This phenotype was due to reduced long bone size, poor cortical bone development, reduced Ki67+ proliferative chondrocytes and decreased proliferative zone (PZ) width in the GP. Expression of pMAPK, but not pSTAT3, was increased in the GPs of Socs3Δ/Δcol2 mice relative to littermate controls. Overexpression of FGFR3 in HEK293T cells increased Fibroblast Growth Factor 18 (FGF18)-dependent Mitogen-activated protein kinase (MAPK) phosphorylation, while concomitant expression of SOCS3 reduced FGFR3 expression and abrogated MAPK signaling., Conclusion: Our results suggest a potential role for SOCS3 in GP chondrocyte proliferation by regulating FGFR3-dependent MAPK signaling in response to FGF18., (Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
46. The Pyroptotic Cell Death Effector Gasdermin D Is Activated by Gout-Associated Uric Acid Crystals but Is Dispensable for Cell Death and IL-1β Release.
- Author
-
Rashidi M, Simpson DS, Hempel A, Frank D, Petrie E, Vince A, Feltham R, Murphy J, Chatfield SM, Salvesen GS, Murphy JM, Wicks IP, and Vince JE
- Subjects
- Acrylamides pharmacology, Animals, Caspase 1 metabolism, Cathepsins antagonists & inhibitors, Female, Intracellular Signaling Peptides and Proteins genetics, Macrophages immunology, Macrophages metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Nitrofurans pharmacology, Peritonitis chemically induced, Peritonitis immunology, Peritonitis pathology, Phosphate-Binding Proteins genetics, Protein Kinases genetics, Styrenes pharmacology, Sulfonamides pharmacology, Gout pathology, Interleukin-1beta metabolism, Intracellular Signaling Peptides and Proteins metabolism, Phosphate-Binding Proteins metabolism, Pyroptosis physiology, Uric Acid metabolism
- Abstract
The pyroptotic cell death effector gasdermin D (GSDMD) is required for murine models of hereditary inflammasome-driven, IL-1β-dependent, autoinflammatory disease, making it an attractive therapeutic target. However, the importance of GSDMD for more common conditions mediated by pathological IL-1β activation, such as gout, remain unclear. In this study, we address whether GSDMD and the recently described GSDMD inhibitor necrosulfonamide (NSA) contribute to monosodium urate (MSU) crystal-induced cell death, IL-1β release, and autoinflammation. We demonstrate that MSU crystals, the etiological agent of gout, rapidly activate GSDMD in murine macrophages. Despite this, the genetic deletion of GSDMD or the other lytic effector implicated in MSU crystal killing, mixed lineage kinase domain-like (MLKL), did not prevent MSU crystal-induced cell death. Consequently, GSDMD or MLKL loss did not hinder MSU crystal-mediated release of bioactive IL-1β. Consistent with in vitro findings, IL-1β induction and autoinflammation in MSU crystal-induced peritonitis was not reduced in GSDMD-deficient mice. Moreover, we show that the reported GSDMD inhibitor, NSA, blocks inflammasome priming and caspase-1 activation, thereby preventing pyroptosis independent of GSDMD targeting. The inhibition of cathepsins, widely implicated in particle-induced macrophage killing, also failed to prevent MSU crystal-mediated cell death. These findings 1) demonstrate that not all IL-1β-driven autoinflammatory conditions will benefit from the therapeutic targeting of GSDMD, 2) document a unique mechanism of MSU crystal-induced macrophage cell death not rescued by pan-cathepsin inhibition, and 3) show that NSA inhibits inflammasomes upstream of GSDMD to prevent pyroptotic cell death and IL-1β release., (Copyright © 2019 by The American Association of Immunologists, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
47. SIDT1 Localizes to Endolysosomes and Mediates Double-Stranded RNA Transport into the Cytoplasm.
- Author
-
Nguyen TA, Smith BRC, Elgass KD, Creed SJ, Cheung S, Tate MD, Belz GT, Wicks IP, Masters SL, and Pang KC
- Subjects
- Animals, Cells, Cultured, DNA immunology, Membrane Transport Proteins genetics, Mice, Mice, Inbred C57BL, Mice, Knockout, Nucleotide Transport Proteins genetics, Poly I-C immunology, RNA Transport genetics, Cardiovirus Infections immunology, Cytoplasm metabolism, Encephalomyocarditis virus physiology, Endosomes metabolism, Herpes Simplex immunology, Herpesvirus 1, Human physiology, Lysosomes metabolism, Membrane Transport Proteins metabolism, Nucleotide Transport Proteins metabolism
- Abstract
dsRNA is a common by-product of viral replication and acts as a potent trigger of antiviral immunity. SIDT1 and SIDT2 are closely related members of the SID-1 transmembrane family. SIDT2 functions as a dsRNA transporter and is required to traffic internalized dsRNA from endocytic compartments into the cytosol for innate immune activation, but the role of SIDT1 in dsRNA transport and in the innate immune response to viral infection is unclear. In this study, we show that Sidt1 expression is upregulated in response to dsRNA and type I IFN exposure and that SIDT1 interacts with SIDT2. Moreover, similar to SIDT2, SIDT1 localizes to the endolysosomal compartment, interacts with the long dsRNA analog poly(I:C), and, when overexpressed, enhances endosomal escape of poly(I:C) in vitro. To elucidate the role of SIDT1 in vivo, we generated SIDT1-deficient mice. Similar to Sidt2
-/- mice, SIDT1-deficient mice produced significantly less type I IFN following infection with HSV type 1. In contrast to Sidt2-/- mice, however, SIDT1-deficient animals showed no impairment in survival postinfection with either HSV type 1 or encephalomyocarditis virus. Consistent with this, we observed that, unlike SIDT2, tissue expression of SIDT1 was relatively restricted, suggesting that, whereas SIDT1 can transport extracellular dsRNA into the cytoplasm following endocytosis in vitro, the transport activity of SIDT2 is likely to be functionally dominant in vivo., (Copyright © 2019 by The American Association of Immunologists, Inc.)- Published
- 2019
- Full Text
- View/download PDF
48. The Selective Expansion and Targeted Accumulation of Bone Marrow-Derived Macrophages Drive Cardiac Vasculitis.
- Author
-
Stock AT, Collins N, Smyth GK, Hu Y, Hansen JA, D'Silva DB, Jama HA, Lew AM, Gebhardt T, McLean CA, and Wicks IP
- Subjects
- Animals, Cell Movement, Cell Proliferation, Coronary Vessels pathology, Disease Models, Animal, Humans, Membrane Transport Proteins metabolism, Mice, Receptors, CCR2 metabolism, Embryonic Stem Cells cytology, Macrophages immunology, Mucocutaneous Lymph Node Syndrome immunology, Myocarditis immunology, Myocardium immunology, Pericardium immunology, Vasculitis immunology
- Abstract
The adult heart contains macrophages derived from both embryonic and adult bone marrow (BM)-derived precursors. This population diversity prompted us to explore how distinct macrophage subsets localize within the heart, and their relative contributions in cardiac disease. In this study, using the reciprocal expression of Lyve-1 and Ccr2 to distinguish macrophages with distinct origins, we show that, in the steady state, both embryonic (Lyve
pos ) and BM-derived (Ccr2pos ) macrophages populate the major vessels of the heart in mice and humans. However, cardiac macrophage populations are markedly perturbed by inflammation. In a mouse model of Kawasaki disease, BM-derived macrophages preferentially increase during acute cardiac inflammation and selectively accumulate around major cardiac vessels. The accumulation of BM-derived macrophages coincides with the loss of their embryonic counterparts and is an initiating, essential step in the emergence of subsequent cardiac vasculitis in this experimental model. Finally, we demonstrate that the accumulation of Ccr2pos macrophages (and the development of vasculitis) occurs in close proximity to a population of Ccr2 chemokine ligand-producing epicardial cells, suggesting that the epicardium may be involved in localizing inflammation to cardiac vessels. Collectively, our findings identify the perivascular accumulation of BM-derived macrophages as pivotal in the pathogenesis of cardiac vasculitis and provide evidence about the mechanisms governing their recruitment to the heart., (Copyright © 2019 by The American Association of Immunologists, Inc.)- Published
- 2019
- Full Text
- View/download PDF
49. TNF and IL-1 Play Essential but Temporally Distinct Roles in Driving Cardiac Inflammation in a Murine Model of Kawasaki Disease.
- Author
-
Stock AT, Jama HA, Hansen JA, and Wicks IP
- Subjects
- Animals, Antigens, Fungal immunology, Disease Models, Animal, Humans, Interleukin-1 genetics, Mice, Mice, Inbred C57BL, Mice, Knockout, Signal Transduction, Tumor Necrosis Factor-alpha genetics, Candida albicans immunology, Coronary Vessels pathology, Interleukin-1 metabolism, Mucocutaneous Lymph Node Syndrome immunology, Myocarditis immunology, Tumor Necrosis Factor-alpha metabolism, Vasculitis immunology
- Abstract
Kawasaki disease (KD) is a leading cause of pediatric heart disease, characterized by the emergence of life-threatening coronary vasculitis. Identifying which cytokines drive KD has been a major research goal, and both TNF and IL-1 have been identified as potential candidates. Using a murine model of KD induced by the injection of the water-soluble component of Candida albicans , we therefore undertook a mechanistic study to determine how and when these two cytokines mediate cardiac inflammation. In this study, we show that TNF signaling is active in the acute phase of cardiac inflammation, which is characterized by a diffuse myocarditis that precedes the development of coronary vasculitis. Mechanistically, TNF is produced by the myeloid cells and triggers acute cardiac inflammation by stimulating both stromal and immune compartments of the heart. In contrast to this early involvement for TNF, IL-1 signaling is dispensable for the development of acute myocarditis. Critically, although mice deficient in IL-1 signaling have extensive acute inflammation following C. albicans water-soluble complex challenge, they do not develop coronary vasculitis. Thus, TNF and IL-1 appear to play temporally distinct roles in KD, with TNF being active in acute cardiac inflammation and IL-1 in the subsequent development of coronary vasculitis. These observations have important implications for understanding the progression of cardiac pathology in KD and the relative therapeutic use of targeting these cytokines., (Copyright © 2019 by The American Association of Immunologists, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
50. NFIL3 mutations alter immune homeostasis and sensitise for arthritis pathology.
- Author
-
Schlenner S, Pasciuto E, Lagou V, Burton O, Prezzemolo T, Junius S, Roca CP, Seillet C, Louis C, Dooley J, Luong K, Van Nieuwenhove E, Wicks IP, Belz G, Humblet-Baron S, Wouters C, and Liston A
- Subjects
- Animals, Child, Disease Models, Animal, Female, Humans, Immunity, Innate genetics, Interleukin-1beta genetics, Interleukin-1beta metabolism, Mice, Twins, Monozygotic genetics, Exome Sequencing, Arthritis, Juvenile genetics, Arthritis, Juvenile immunology, Basic-Leucine Zipper Transcription Factors genetics, Basic-Leucine Zipper Transcription Factors immunology, Mutation immunology
- Abstract
Objectives: NFIL3 is a key immunological transcription factor, with knockout mice studies identifying functional roles in multiple immune cell types. Despite the importance of NFIL3, little is known about its function in humans., Methods: Here, we characterised a kindred of two monozygotic twin girls with juvenile idiopathic arthritis at the genetic and immunological level, using whole exome sequencing, single cell sequencing and flow cytometry. Parallel studies were performed in a mouse model., Results: The patients inherited a novel p.M170I in NFIL3 from each of the parents. The mutant form of NFIL3 demonstrated reduced stability in vitro. The potential contribution of this mutation to arthritis susceptibility was demonstrated through a preclinical model, where Nfil3-deficient mice upregulated IL-1β production, with more severe arthritis symptoms on disease induction. Single cell sequencing of patient blood quantified the transcriptional dysfunctions present across the peripheral immune system, converging on IL-1β as a pivotal cytokine., Conclusions: NFIL3 mutation can sensitise for arthritis development, in mice and humans, and rewires the innate immune system for IL-1β over-production., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.